Cassava Sciences, Inc. SAVA
1.32 USD 0.00 (+0.00%)
May 22, 2026, 12:35 PM EDT
1.27 Day range 1.35
2.23 52-week range 42.20
- YTD
- -33.33%
- 1 year
- -25.42%
News
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
prnewswire.com HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is…
globenewswire.com Cassava Announces Agreement to Settle Securities Class Action Litigation AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold Cassava Sciences Inc. (NASDAQ: SAVA) received a formal letter from the U.S. Food and Drug Administration (FDA) related to the company's trial for simufilam- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
defenseworld.net Comparing Cassava Sciences (NASDAQ:SAVA) and Carisma Therapeutics (NASDAQ:CARM) Carisma Therapeutics (NASDAQ: CARM - Get Free Report) and Cassava Sciences (NASDAQ: SAVA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare…
businesswire.com Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary…
globenewswire.com Cassava Sciences Appoints Dawn C. Bir to the Board of Directors AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Why Super League Enterprise Shares Are Trading Higher By 200%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
globenewswire.com Cassava Reports Q2 2025 Financials Results and Provides Business Update AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for…
globenewswire.com Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational…
globenewswire.com Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy AUSTIN, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel treatments for…
globenewswire.com Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program AUSTIN, Texas, June 30, 2025…- benzinga.com 'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%20Lumipulse%20G%20pTau217%2F%C3%9F,and%20symptoms%20of%20the%20disease.
globenewswire.com Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC As SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially…
globenewswire.com Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational…
zacks.com Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street…
zacks.com Is the Future Bleak for SAVA Stock Following Another Setback? The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects.
reuters.com Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental, soon-to-be-discontinued…
zacks.com SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second late-stage study.
benzinga.com Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop Cassava Sciences Inc. SAVA on Tuesday shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer's disease.
globenewswire.com Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing a novel,…
zacks.com Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock? Cassava Sciences (SAVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
benzinga.com Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday? Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to…
globenewswire.com Cassava Sciences Reports 2024 Financial Results and Provides Business Update AUSTIN, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Crude Oil Falls Over 4%; US Trade Deficit Narrows In August 
benzinga.com This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- benzinga.com IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
benzinga.com Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
benzinga.com Nasdaq Dips 300 Points; Johnson & Johnson Earnings Top Estimates - benzinga.com Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.
- benzinga.com Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.
- benzinga.com Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers
- benzinga.com Wyndham Hotels & Resorts, Olink Holding And Other Big Stocks Moving Higher On Tuesday U.S. stocks traded lower, with the Dow Jones falling around 50 points on Tuesday. Here are some big stocks recording gains in today’s session.
- benzinga.com Why Belden Shares Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreement for the acquisition of NextTrip Holdings, Inc.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.
benzinga.com Jim Cramer Says No To This Fintech Titan With Declining Margins: 'I Think It's A Value Trap' On CNBC’s "Mad Money Lightning Round," Jim Cramer said ONEOK, Inc's (NYSE: OKE) management is terrific. "The CFO Walter Hulse is like you and me, a Jersey-ite.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 210 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 201 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During the Friday's sesion, 157 stocks hit new 52-week lows.